Abionic's New POC Sepsis Test On Rapid Move To Market
Swiss start-up Abionic has CE marked rapid tests for sepsis and iron deficiency, designed to run on its diagnostics platform abioSCOPE. The new sepsis test is based on a new biomarker PSP which has shown to be superior to current tests in detecting this life threatening condition early.
You may also be interested in...
Swiss diagnostics developer Abionic has scored CHF20m ($21m) in Series C financing from a syndicate of high-net-worth individuals to kickstart a multinational study into the efficacy of its Pancreatic Stone Protein (PSP) test for rapid sepsis risk assessment and management.
The 20 non-US medical device approvals in January, including eight in in vitro diagnostics, four in orthopedics, and three in cardiovascular devices. Big medtech players Medtronic and Abbott, accompanied by much smaller Swiss IVD firm Abionic, led the charge and bagged more OUS approvals than most.
One year on from its IPO on Euronext Brussels, abdominal implant maker Sequana Medical has secured €19m ($21m) in an equity placement. The company said it had been backed by new and existing investors.